Major Growth Driver Identified in 2025 Conjugate Vaccine Market: The Surge In Conjugate Vaccine Use Drives Market Expansion

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Conjugate Vaccine Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent years, the size of the conjugate vaccine market has seen a swift expansion. The market, originating from an $18.9 billion base in 2024, is projected to scale up to $21.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.5%. Factors contributing to this growth throughout the historic period include the burden of disease, government-run immunization campaigns, heightened levels of awareness, an intensified focus on pediatric vaccination, and trends in preventive healthcare.

Conjugate Vaccine Market Size Forecast: What's the Projected Valuation by 2029?
In the coming years, a swift expansion is anticipated in the conjugate vaccine market. The market is projected to reach $33.99 billion by 2029, with a compound annual growth rate (CAGR) of 12.4%. Factors fueling this surge during the predicted period include increasing immunization policies, shifting demographics due to an aging population, and the introduction of new vaccine indications. Issues related to global health security, multinational cooperation, and the implications of economic development also contribute to this growth. The future trends expected to shape this period are collaboration and partnerships aimed at vaccine distribution, specialized strategies for populations at high risk, the application of vaccines to tackle emerging infectious diseases, progression in the production technology for vaccines, and worldwide health drives promoting equitable access to vaccines.

View the full report here:
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

What Are the Drivers Transforming the Conjugate Vaccine Market?
The conjugate vaccine market is set to expand owing to the rising application of conjugate vaccines among adults. These vaccines are specifically developed to encourage heightened immune response to bacterial capsular polysaccharides, thereby bolstering the body's capability to fend off bacterial infections. Administering conjugate vaccines in adults minimizes the possibilities of serious sickness, complications, and the spread of bacterial diseases due to the establishment of a formidable immune response. For example, the UK Health Security Agency (UKHSA), reported in June 2024, that the '6-in-1' vaccine coverage in the UK remained stable at 91.7% over the past 12 months. Similarly, the pneumococcal conjugate vaccine (PCV) first dose kept its rate at 93.7%. The coverage of Rotavirus saw a 0.6% hike, touching 89.3%, while the meningitis B vaccine's (MenB2) second dose level increased marginally by 0.1% to reach 91.5%. Hence, the growing application of conjugate vaccines in adults is a significant factor fuelling the surge in the conjugate vaccine market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

What Trends Will Shape the Conjugate Vaccine Market Through 2029 and Beyond?
A significant trend gaining traction in the conjugate vaccine market is the innovation in conjugate vaccines. Firms in this market are prioritizing the creation of novel conjugate vaccines to maintain their market standing. For example, Pfizer Inc., an American pharmaceutical and biotechnology firm, introduced Prevnar 20, a 20-valent pneumococcal conjugate vaccine, in Canada in June 2022. This vaccine aims to prevent pneumonia and serious pneumococcal infections in adults 18 years and older. In addition to the 13 serotypes already included in PREVNAR 13, Prevnar 20 incorporates conjugates for seven extra serotypes linked to invasive pneumococcal disease, high mortality rates, antibiotic resistance, and meningitis.

Which Segments in the Conjugate Vaccine Market Offer the Most Profit Potential?
The conjugate vaccine market covered in this report is segmented -

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:
1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines
2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

Which Firms Dominate the Conjugate Vaccine Market by Market Share and Revenue in 2025?
Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Which Regions Offer the Highest Growth Potential in the Conjugate Vaccine Market?
North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10850

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.